keyword
MENU ▼
Read by QxMD icon Read
search

KP-1461

keyword
https://www.readbyqxmd.com/read/22738014/safety-tolerability-and-efficacy-of-kp-1461-as-monotherapy-for-124-days-in-antiretroviral-experienced-hiv-type-1-infected-subjects
#1
Charles Hicks, Patrick Clay, Robert Redfield, Jay Lalezari, Ralph Liporace, Stefan Schneider, Michael Sension, MaryPeace McRae, Jean-Pierre Laurent
Treatment of HIV infection with conventional antiretroviral therapy (ART) is a lifelong challenge with significant long-term risks of adverse events and treatment failure-induced HIV resistance being major concerns. One potential alternative to standard treatment is the use of viral decay accelerators, antiviral agents that theoretically can drive the rate of viral mutation beyond the compensatory capacity of the virus, thereby inducing viral extinction. One such drug, KP-1461, was tested in a population of HIV-infected persons not receiving ART to assess the safety, tolerability, and efficacy of the strategy in vivo...
February 2013: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/21593403/safety-tolerability-and-pharmacokinetics-of-kp-1461-in-phase-i-clinical-studies-a-single-oral-dose-study-in-non-hiv-infected-adults-and-a-14-day-dose-escalating-study-in-highly-antiretroviral-experienced-hiv-infected-adults
#2
RANDOMIZED CONTROLLED TRIAL
Patrick G Clay, Marypeace McRae, Jean-Pierre Laurent
BACKGROUND: KP-1461 is a prodrug to KP-1212. KP-1212 is a viral mutagen designed to increase viral error rate. METHODS: We describe 2 phase I studies: KP1461-101 (double-blind, placebo-controlled, single, escalating doses, 100 to 1600 mg study in 42 non-HIV-infected participants) and KP-1461-102 (double-blind placebo-controlled dose escalation 14-day study in HIV-infected participants, 400-3200 mg). Primary objectives were safety/tolerability. Secondary objectives included pharmacokinetic analysis with exploratory objective to characterize KP-1212 effects on viral load...
July 2011: Journal of the International Association of Physicians in AIDS Care: JIAPAC
https://www.readbyqxmd.com/read/21032953/kp-1461-a-novel-anti-hiv-drug-in-limbo
#3
David Evans
The path of an experimental drug from the laboratory to U.S. Food and Drug Administration (FDA) approval is typically long, rocky, and uncertain. It is especially so for a drug that turns common wisdom on its head. Take KP-1461, a new type of antiretroviral drug from Koronis Pharmaceuticals in Seattle. Unlike all of the currently approved anti-HIV drugs, which aim to reduce the amount of virus in the body by blocking viral replication, KP-1461 was designed not to inhibit replication, but rather to force newly created HIV to become less able to infect human cells...
January 2010: BETA Bulletin of Experimental Treatments for AIDS: a Publication of the San Francisco AIDS Foundation
https://www.readbyqxmd.com/read/18814370/getting-the-most-from-available-antiretroviral-therapies
#4
Liz Highleyman
Two decades after the approval of the first antiretroviral drugs, combination HAART has dramatically lowered the risk of illness and death for people with HIV. The year 2007 was another milestone, witnessing the approval of the first agents in two new anti-HIV drug classes--CCR5 antagonists and integrase inhibitors--that provide new options for treatment-experienced patients. Today, however, the anti-HIV drug pipeline is relatively sparse, with no blockbusters in the foreseeable future. While the first HIV maturation inhibitor, bevirimat, continues to slowly make its way through clinical trials, another once-promising agent that works by a completely novel mechanism, Koronis Pharmaceuticals' KP-1461, was recently put on hold after laboratory tests indicated that it did not demonstrate the expected antiviral activity...
2008: BETA Bulletin of Experimental Treatments for AIDS: a Publication of the San Francisco AIDS Foundation
https://www.readbyqxmd.com/read/18411488/new-kind-of-antiretroviral-kp-1461-clinical-trial-recruiting-interview-with-stephen-becker-m-d
#5
Stephen Becker
KP-1461, an experimental HIV drug already in a phase II trial, works so differently from other antiretrovirals that at first glance it looked like science fiction, and we found it hard to take seriously as a current possibility today. In fact this drug is highly credible, and based on elegant science that goes back at least 25 years. KP-1461 is the only antiretroviral in human use or testing that can eradicate HIV from laboratory cell cultures. No one knows how it will work in people -- but we might know by the second quarter of 2008, when the current phase II trial could be complete...
July 2007: AIDS Treatment News
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"